Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YM543
- Development stage
- Phase 2
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
YM543 (also known as ASP-543) is a potent and selective small molecule inhibitor of sodium-glucose cotransporter 2 (SGLT2), developed for the treatment of type 2 diabetes mellitus. SGLT2 is primarily expressed in the kidney and plays a key role in renal glucose reabsorption. By inhibiting SGLT2, YM543 reduces blood glucose levels by increasing urinary glucose excretion. Preclinical studies demonstrated that oral administration of YM543 significantly reduced hyperglycemia and improved glucose tolerance in diabetic animal models without affecting normoglycemia in healthy animals. The drug advanced to phase II clinical trials for type 2 diabetes mellitus but development was discontinued before approval[4][6][7].
- Other names
- YM-543 free acidYM543 free acidYM 543 free acid655237-16-4CHEMBL2397450CHEMBL-2397450CHEMBL 239745000X1DX441H
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on YM543.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YM543.